Head to Head Review: Aclarion (NASDAQ:ACON) vs. Schrodinger (NASDAQ:SDGR)

Aclarion (NASDAQ:ACON) and Schrodinger (NASDAQ:SDGR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Valuation & Earnings

This table compares Aclarion and Schrodinger”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80,000.00	59.76	-$7.23 million	($7.40)	-0.22
Schrodinger	$255.87 million	8.60	-$103.26 million	($0.79)	-37.75

Aclarion has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Aclarion has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500.

Insider & Institutional Ownership

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 79.0% of Schrodinger shares are owned by institutional investors. 0.0% of Aclarion shares are owned by insiders. Comparatively, 10.1% of Schrodinger shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Aclarion and Schrodinger’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,948.81%	-59.34%	-56.12%
Schrodinger	-20.98%	-16.37%	-8.19%

Analyst Recommendations

This is a breakdown of current ratings for Aclarion and Schrodinger, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	0	1	0	2.00
Schrodinger	1	3	4	0	2.38

Aclarion currently has a consensus target price of $7.50, indicating a potential upside of 351.81%. Schrodinger has a consensus target price of $26.67, indicating a potential downside of 10.57%. Given Aclarion’s higher possible upside, equities analysts plainly believe Aclarion is more favorable than Schrodinger.

Summary

Schrodinger beats Aclarion on 10 of the 14 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About Schrodinger

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.